MX2016004847A - Derivados de piperazina y su uso como medicamento. - Google Patents

Derivados de piperazina y su uso como medicamento.

Info

Publication number
MX2016004847A
MX2016004847A MX2016004847A MX2016004847A MX2016004847A MX 2016004847 A MX2016004847 A MX 2016004847A MX 2016004847 A MX2016004847 A MX 2016004847A MX 2016004847 A MX2016004847 A MX 2016004847A MX 2016004847 A MX2016004847 A MX 2016004847A
Authority
MX
Mexico
Prior art keywords
piperazine derivatives
medicament
compounds
general formula
glyt1
Prior art date
Application number
MX2016004847A
Other languages
English (en)
Other versions
MX370006B (es
Inventor
Christoph Hoenke
Holger Rosenbrock
Riccardo Giovannini
Uta Lessel
Bernhard Schmid
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2016004847A publication Critical patent/MX2016004847A/es
Publication of MX370006B publication Critical patent/MX370006B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Las presentes invenciones se refieren a derivados sustituidos de piperazina de la Fórmula general (I) (ver Fórmula) y a la fabricación de los compuestos, las composiciones farmacéuticas que comprenden un compuesto de acuerdo con la Fórmula general (I), y el uso de los compuestos para el tratamiento de diversas condiciones médicas relacionadas con el transportador de glicina-1 (G1yT1).
MX2016004847A 2013-10-16 2014-10-15 Derivados de piperazina y su uso como medicamento. MX370006B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13188904 2013-10-16
PCT/EP2014/072085 WO2015055698A1 (en) 2013-10-16 2014-10-15 Piperazine derivatives and the use thereof as medicament

Publications (2)

Publication Number Publication Date
MX2016004847A true MX2016004847A (es) 2016-07-19
MX370006B MX370006B (es) 2019-11-28

Family

ID=49354583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004847A MX370006B (es) 2013-10-16 2014-10-15 Derivados de piperazina y su uso como medicamento.

Country Status (21)

Country Link
US (1) US9233953B2 (es)
EP (1) EP3057963B1 (es)
JP (1) JP6483105B2 (es)
KR (1) KR102281284B1 (es)
CN (1) CN105636961B (es)
AR (1) AR098037A1 (es)
AU (1) AU2014336258B2 (es)
BR (1) BR112016008062B1 (es)
CA (1) CA2926754C (es)
CL (1) CL2016000884A1 (es)
DK (1) DK3057963T3 (es)
EA (1) EA029313B1 (es)
ES (1) ES2745555T3 (es)
HU (1) HUE047044T2 (es)
IL (1) IL244693B (es)
MX (1) MX370006B (es)
PH (1) PH12016500577A1 (es)
PL (1) PL3057963T3 (es)
TW (1) TW201609716A (es)
UY (1) UY35785A (es)
WO (1) WO2015055698A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN107778257A (zh) * 2016-08-29 2018-03-09 湖南华腾制药有限公司 一种哌嗪衍生物的合成方法
CN106977463A (zh) * 2017-05-31 2017-07-25 湖南华腾制药有限公司 一种联苯取代哌嗪衍生物的合成方法
CN107417679A (zh) * 2017-08-04 2017-12-01 河南农业大学 1,3‑唑类取代吡嗪类化合物的制备方法
JP2023509792A (ja) 2020-01-09 2023-03-09 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
CN102574857B (zh) 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物

Also Published As

Publication number Publication date
KR20160062187A (ko) 2016-06-01
BR112016008062B1 (pt) 2022-11-16
PH12016500577B1 (en) 2016-06-20
US20150105397A1 (en) 2015-04-16
WO2015055698A1 (en) 2015-04-23
JP2016533368A (ja) 2016-10-27
EA029313B1 (ru) 2018-03-30
BR112016008062A2 (es) 2017-08-01
CA2926754C (en) 2021-09-14
NZ718251A (en) 2021-02-26
US9233953B2 (en) 2016-01-12
IL244693A0 (en) 2016-04-21
EP3057963B1 (en) 2019-06-19
TW201609716A (zh) 2016-03-16
KR102281284B1 (ko) 2021-07-23
PL3057963T3 (pl) 2019-12-31
EA201600323A1 (ru) 2016-10-31
MX370006B (es) 2019-11-28
AU2014336258B2 (en) 2018-07-12
PH12016500577A1 (en) 2016-06-20
HUE047044T2 (hu) 2020-04-28
UY35785A (es) 2015-04-30
CA2926754A1 (en) 2015-04-23
CN105636961B (zh) 2019-11-05
CL2016000884A1 (es) 2016-12-30
AR098037A1 (es) 2016-04-27
ES2745555T3 (es) 2020-03-02
IL244693B (en) 2019-08-29
DK3057963T3 (da) 2019-09-16
JP6483105B2 (ja) 2019-03-13
CN105636961A (zh) 2016-06-01
EP3057963A1 (en) 2016-08-24
AU2014336258A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX363456B (es) Compuestos para tratar atrofia muscular espinal.
NZ608116A (en) Triazine-oxadiazoles
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
NZ716840A (en) Combination formulation of two antiviral compounds
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MY197698A (en) Oxysterols and methods of use thereof
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201591195A1 (ru) Новые хинолоновые производные
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
EA201600434A1 (ru) Применение производных бензимидазолпролина
IN2015DN03998A (es)
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
MX364400B (es) Compuestos de tetraciclina.
MX362879B (es) Usos novedosos.
IN2014DN10449A (es)
UA117154C2 (uk) Антагоністи s1p3
EA201490573A1 (ru) Соединение бензотиазолона
MY181682A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU02442A (es)

Legal Events

Date Code Title Description
FG Grant or registration